Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?
In a pooled subcohort analysis of TENAYA and LUCERNE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.
Ocular Surgery News | As genetic counselors, we help patients to make informed decisions about genetic testing.We talk to them about what we know about the genetics of the condition and answer any questions, and then we order genetic testing for them, if that is something they want to do.
PANORAMA trial results show efficacy of proactive anti-VEGF treatment for NPDR healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.